Dr. Reddy's Laboratories Share Price

NSE: DRREDDY
|
Pharmaceuticals

₹ 1,233.00

+₹14.20 (1.17%)
1D
Last updated 16 Oct, 2026, 15:53 IST

Dr. Reddy's Laboratories Share Price Today

As of 18 Oct 2026, Dr. Reddy's Laboratories share price is ₹1,233.00. The stock opened at ₹1,222.00, compared to its previous close of ₹1,218.80. During today's trading session, Dr. Reddy's Laboratories share price moved in the range of ₹1,214.10 to ₹1,233.00, with an average price of ₹1,223.55 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,101.00 and a high of ₹1,414.90. On the performance front, Dr. Reddy's Laboratories share price has increased by 0.95% over the last six months and is down 0.58% on a year-on-year basis.

₹1,214.10
1.17% up today
₹1,233.00
1D LOW
1D HIGH

Dr. Reddy's Laboratories Returns Calculator

Volume
12,61,028
Average traded price
₹1,223.94
Last traded time
03:53:32 16 Oct
Last traded quantity
1
Circuit
L
H
₹1,109.70
₹1,356.30
52-week
L
H
₹1,101.00
₹1,414.90
Mkt Cap Cr
1,02,820.09
P/E
32.3
P/B
2.7
ROA
5.48%
ROE
11.07%
ROCE
12.54%
Quick Ratio
1.35
EV/EBITDA
16.32
Based on fundamentals, this stock's
Step 5 of 5
Performance
Excellent
Dr Reddy's Labs outperforming all market indices
Step 1 of 5
Valuation
Overvalued
Dr Reddy's Labs appears overvalued compared to its peers
Step 4 of 5
Earnings
Good
Dr Reddy's Labs revenue, operating profit and net profit are growing
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROAROEROCEQuick RatioEV/EBITDA
Sun Pharmaceutical Industries4,22,282.9534.855.0511.19%13.74%17.33%2.3121.41
Divis Laboratories2,44,762.0383.6814.614.6%15.32%19.56%3.555.09
Torrent Pharmaceuticals1,73,447.7480.4520.634.87%25.49%13.85%0.7537.36
Zydus Lifesciences1,12,149.3624.424.148.57%18.59%17.35%0.9114.94
Laurus Labs1,11,250.29102.0320.9910.38%16.77%16.14%0.6854.47
Cipla1,07,042.8631.93.117.92%11.27%14.95%2.518.16
Aurobindo Pharma95,512.7325.742.526.34%9.25%11.76%1.1512.27
Mankind Pharma93,967.7645.455.767.36%11.74%13.13%0.7424.75
Lupin89,436.7716.113.9814.47%23.76%24.88%1.429.59
Glenmark Pharma62,766.7734.915.979.03%28.08%32.7%1.2318.56

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

About Dr. Reddy's Laboratories

ISIN
INE089A01031
Sector Market Cap
₹ 102,820.09 Cr

Dr. Reddy's Laboratories is an Indian pharmaceutical company that was founded in 1984 by Kallam Anji Reddy. Headquartered in Hyderabad, the company produces over 190 medications and over 60 active pharmaceutical ingredients (APIs).

The market capitalisation of Dr. Reddy's Laboratories Limited was ₹97,400 crore as of January 4, 2024. The share price of Dr. Reddy's has gained over 10% in the last three years

Business Operations

Dr. Reddy's Laboratories has been an active player in the pharmaceutical sector for more than 20 years. Its expertise lies in Active Pharmaceutical Ingredients (API), boasting a diverse portfolio. They specialise in manufacturing generic medicines with operations in India, Russia, US and Germany.

The company also engages in proprietary products, biologics business and unique formulations conducted primarily in the US. It has introduced Grafeel (Filgrastim), a drug used to fight infections after chemotherapy, and Reditux (Rituximab), an ant-cancer drug.

Dr. Reddy's produces a diverse range of intricate APIs and holds over 1,150 drug master files covering key therapy areas like oncology, cardiovascular, central nervous system and anti-diabetes. With 22 manufacturing facilities worldwide, the company ensures top-quality output and timely supply to markets. Its expertise in Active Pharmaceutical Ingredients (API) spans 8 manufacturing units globally.

The company’s largest manufacturing facility is located in Bachupally, Hyderabad. As of FY22, it has filed 1,071 patents and published over 1,000 papers.

Central to its R&D excellence is the Integrated Product Development Organisation (IPDO) situated in Hyderabad. This extensive campus hosts multiple laboratories, including the latest addition, a nutraceutical R&D centre. These cutting-edge labs are powered by a diverse team of scientists recruited from leading institutions worldwide.

The dedicated efforts of Dr. Reddy's in product development support a portfolio exceeding 1,000 products. The pharma giant has an R&D team comprising over 150 doctorates.

The company is focused on research and has a strong team of over 3,000 scientists in 8 R&D facilities. As of March 31, 2023, Dr. Reddy's is powered by a workforce of 25,498 permanent employees and workers in 74 countries.

The business of Dr. Reddy's Laboratories in branded generics thrives not only in India but also in emerging markets globally. Its branded products reach over 30 countries, spanning Asia, Africa, Australia, New Zealand, Russia, Romania, China and Latin America.

The company's growth rate has doubled in the past four years. It has reached a prominent position in crucial therapy areas like oncology, gastroenterology, allergy, diabetes and pain management. Within its Indian operations, it structures its business according to therapies, managing over 300 brands. Its extensive reach to healthcare professionals is facilitated by a field force comprising approximately 7,500 members.

Dr. Reddy's Laboratories Financial Highlights

  • Revenue: Dr. Reddy's Laboratories reported revenue of ₹35,058.60 crore in FY26 vs ₹33,741.20 crore in FY25. It showed an increase of 3.90% on a yearly basis.
  • Operating Profit: Dr. Reddy's Laboratories reported an operating profit of ₹5,392.70 crore in FY26 vs ₹7,679.50 crore in FY25. It showed a decrease of 29.78% on a year-on-year basis.
  • Net Profit: Dr. Reddy's Laboratories reported a net profit of ₹4,157.60 crore in FY26 vs ₹5,725.20 crore in FY25. It showed a decrease of 27.38% on a yearly basis.

Dr. Reddy's Laboratories Quarterly Result Highlights

  • Dr. Reddy's Laboratories reported revenue of ₹8,454.50 crore in Jun 2026, compared with ₹8,021.80 crore in Mar 2026, representing an increase of 5.39% on a quarter-on-quarter (QoQ) basis.
  • Dr. Reddy's Laboratories reported an operating profit of ₹553.30 crore in Jun 2026, compared with ₹199.70 crore in Mar 2026, representing an increase of 177.07% on a quarter-on-quarter (QoQ) basis.
  • Dr. Reddy's Laboratories reported a profit of ₹435.60 crore in Jun 2026, compared with ₹221.30 crore in Mar 2026, reflecting an increase of 96.84% on a QoQ basis.
  • The earnings per share (EPS) of Dr. Reddy's Laboratories stood at ₹50.41 during Jun 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Know more
Promoters
26.64%
FII
32.07%
Other DII
18.58%
Retail and other
9.55%
Mutual funds
13.16%
Foreign Institutional Investor (FII)
FII shareholding by period
Sep 202535.52%
Dec 202533.20%
Mar 202633.08%
Jun 202632.07%
1 day
+1.17%
1 week
+3.01%
1 month
+8.16%
1 year
-0.58%
3 years
+12.23%
5 years
+24.33%
Day
Open / Close
Change %
16 Oct 26
₹1,222.00 / ₹1,233.00
+1.17%
15 Oct 26
₹1,211.10 / ₹1,218.80
+0.23%
14 Oct 26
₹1,234.20 / ₹1,216.00
-1.94%
13 Oct 26
₹1,230.90 / ₹1,240.00
+0.86%
Show more

Dr. Reddy's Laboratories Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹33,700.20₹32,643.90₹28,011.10₹24,669.70
Other Income₹1,358.40₹1,097.30₹894.30₹1,055.50
Total Revenue₹35,058.60₹33,741.20₹28,905.40₹25,725.20
Total Expenses₹29,679.30₹26,083.40₹21,719.10₹19,713.70
Profit Before Tax₹5,392.70₹7,679.50₹7,201.00₹6,048.50
Tax₹1,235.10₹1,954.30₹1,623.10₹1,541.20
Profit After Tax₹4,157.60₹5,725.20₹5,577.90₹4,507.30
EPS - Basic₹50.41₹67.89₹67.04₹271.47
EPS - Diluted₹50.35₹67.79₹66.92₹270.90

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹5,392.70₹7,679.50₹7,201.00₹6,048.50
Income before WC changes₹8,100.90₹9,641.00₹8,566.20₹7,744.40
Change in Assets-₹1,532.30-₹2,303.60-₹2,649.90-₹840.60
Change in Liabilities₹457.70-₹695.30₹631.70₹55.10
Change in WC-₹1,074.60-₹2,998.90-₹2,018.20-₹785.50
Cash flow from Operations₹5,673.70₹4,642.80₹4,543.30₹5,887.50
Cash flow from Investing-₹6,549.30-₹5,807.70-₹4,028.30-₹4,137.30
Cash flow from Financing₹829.00₹1,891.10-₹376.30-₹2,686.10
Total Cash Flow-₹46.60₹726.20₹138.70-₹935.90
Cash (Start of the year)₹1,459.30₹710.70₹577.90₹1,485.20
Cash (End of the year)₹1,536.80₹1,459.30₹710.70₹577.90

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹27,944.10₹24,408.50₹14,058.50₹11,859.60
Current Assets₹30,179.30₹25,018.10₹24,805.30₹20,425.50
Total Assets₹58,123.40₹49,426.60₹38,863.80₹32,285.10
Current Liabilities₹16,747.40₹13,033.80₹9,588.00₹8,572.10
Net Current Asset₹13,431.90₹11,984.30₹15,217.30₹11,853.40
Non-Current Liabilities₹3,145.10₹2,465.40₹1,021.00₹426.90
Equity Capital₹38,230.90₹33,927.40₹28,254.80₹23,286.10
Total Equity & Liabilities₹58,123.40₹49,426.60₹38,863.80₹32,285.10

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹20,532.80₹23,115.40₹19,483.80₹16,962.50
Other Income₹1,689.60₹1,003.40₹862.30₹591.30
Total Revenue₹22,222.40₹24,118.80₹20,346.10₹17,553.80
Total Expenses₹17,971.10₹16,882.90₹14,554.80₹13,687.80
Profit Before Tax₹4,251.30₹7,235.90₹5,791.30₹3,866.00
Tax₹1,031.60₹1,886.50₹1,449.30₹1,253.20
Profit After Tax₹3,219.70₹5,349.40₹4,342.00₹2,612.80
EPS - Basic₹38.68₹64.22₹52.19₹157.37
EPS - Diluted₹38.64₹64.13₹52.09₹157.03

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹4,251.30₹7,235.90₹5,791.30₹3,866.00
Income before WC changes₹4,742.30₹8,050.30₹6,393.30₹4,911.80
Change in Assets₹999.10-₹2,179.10-₹1,558.00₹556.80
Change in Liabilities-₹133.60-₹59.80-₹66.10₹367.00
Change in WC₹865.50-₹2,238.90-₹1,624.10₹923.80
Cash flow from Operations₹4,660.50₹4,225.00₹3,449.70₹5,052.90
Cash flow from Investing-₹5,784.70-₹5,697.60-₹3,430.30-₹3,447.60
Cash flow from Financing₹1,116.80₹1,590.70₹68.10-₹2,696.90
Total Cash Flow-₹7.40₹118.10₹87.50-₹1,091.60
Cash (Start of the year)₹319.70₹201.40₹112.30₹1,159.50
Cash (End of the year)₹337.50₹319.70₹201.40₹112.30

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹25,078.90₹21,787.90₹12,543.40₹11,586.50
Current Assets₹18,523.20₹16,503.00₹17,815.90₹13,788.30
Total Assets₹43,602.10₹38,290.90₹30,359.30₹25,374.80
Current Liabilities₹11,142.50₹8,651.80₹5,538.10₹4,439.70
Net Current Asset₹7,380.70₹7,851.20₹12,277.80₹9,348.60
Non-Current Liabilities₹1,094.00₹782.50₹580.40₹460.90
Equity Capital₹31,365.60₹28,856.60₹24,240.80₹20,474.20
Total Equity & Liabilities₹43,602.10₹38,290.90₹30,359.30₹25,374.80
* All values are in INR Crore
Qty
Bid
0
0
0
0
0
0
0
0
0
0
Ask
Qty
1233
4207
0
0
0
0
0
0
0
0
Bid Total: 0
Ask Total: 4207
Buy orders: 0%
Sell orders: 100%
Bearish
2
Neutral
6
Bullish
0
Slightly Bearish
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
57.84
Neutral
ATR (14)
29.36
Neutral
STOCH(9,6)
78.8
Neutral
STOCH RSI (14)
50.39
Neutral
ADX(9)
23.94
Bearish
UO(9)
58.94
Neutral
ROC(12)
-1.51
Bearish
WillR(14)
-23.13
Neutral
Period
Simple value
Exponential vaue
5D
1227.44
1223.25
10D
1212.9
1217.63
20D
1212.4
1208.52
50D
1187.47
1202.33
100D
1224.04
1215.84
Volume trend — traded volume by day
16 Oct12L
15 Oct13L
14 Oct16L
13 Oct24L
12 Oct17L
Average16L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks
Dr. Reddy's Laboratories
Pharmaceuticals
Add Stock
Add Another

Dr. Reddy's Laboratories Share Price FAQs

Disclaimer: The information on this page, including prices, charts, financials, ratios, and other data, is provided for informational and educational purposes only. It is not investment advice, a research report, or a recommendation or solicitation to buy, sell, or hold any security. Data is sourced from third parties and exchanges, may be delayed, and is not guaranteed to be accurate, complete, or timely. Upstox is not liable for any loss arising from its use.